Project Grant R21HL177570
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $410K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart Lung and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded a $128,085 project grant to The Leland Stanford Junior University (Stanford University) to investigate the role of the COUP-TFII transcription factor in human vein development. The research aims to establish whether COUP-TFII is required for human vein endothelial cell specification and identify the specific protein domains of COUP-TFII involved. The project...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $2,442,173 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) to identify genes and pathways that influence the risk of vascular diseases such as coronary artery disease (CAD) and pulmonary arterial hypertension (PAH). The 5-year award, effective August 15, 2025, will leverage innovative CRISPR genomics approaches to characterize gene...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $769,789 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University). This 4-year grant, effective June 1, 2025, supports the development of a novel injectable, biodegradable hydrogel to provide sustained delivery of the protein therapy neuregulin-1 (NRG1) for the treatment of myocardial infarction (heart attack). The project aims to...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $107,834 project grant to The Leland Stanford Junior University. The grant, which runs from January 21, 2025 to January 2, 2026, aims to investigate the cardiovascular impact of novel gut-hormone agonists, including semaglutide (GLP-1R), tirzepatide (GLP-1R/GIPR), and retatrutide (GLP-1R/GIPR/GCGR). The research will involve comprehensive profiling of...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,903 Project Grant to The Leland Stanford Junior University (Stanford University) on January 31, 2025 under the Cardiovascular Diseases Research (CFDA 93.837) program. The project aims to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity subtypes. Specifically, the study will: (1) retrospectively examine cardiac and oncologic outcomes associated with ICI...
- The National Heart Lung and Blood Institute (NHLBI), part of the U.S. National Institutes of Health (NIH), awarded a $460,625 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Yale University on August 10, 2025. The objective of this project is to develop highly tunable and customizable Tissue Engineered Vascular Conduits (TEVCs) using a novel bioprinting method that can directly print fully physiological materials, including cell-laden tissues. The project aims...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $162,486 to The Leland Stanford Junior University to engineer hematopoietic stem cells to produce B cells that secrete antibodies against PCSK9, a promising treatment for hypercholesterolemia. The research aims to develop a durable, lifelong therapeutic solution by using CRISPR/Cas9 genome editing to target an engineered antibody transgene into a safe-harbor site in...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $159,512.00 to The Leland Stanford Junior University to conduct research on ameliorating cardiac fibrosis using human cardiac organoid models. The project aims to discover treatments for cardiac fibrosis, a hallmark of dilated cardiomyopathy, by validating potential compounds identified in a prior high-throughput screen using complex 3D cardiac organoids...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...